ArticleClinical, cosmetic and investigational dermatology2026
Treatment of Isolated Nail Psoriasis with JAK Inhibitor Tofacitinib: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Isolated nail psoriasis is clinically rare, characterized by nail involvement in the absence of cutaneous lesions, and is often misdiagnosed as onychomycosis. Although tofacitinib, a JAK1/JAK3 inhibitor, is approved for psoriatic arthritis, evidence regarding its efficacy and safety in isolated nail psoriasis remains limited. Case Presentation: We present a 39-year-old female with a 6-year history of refractory isolated nail psoriasis, previously unresponsive to itraconazole, acitretin, topical antifungals, and corticosteroids. The patient received oral tofacitinib 5 mg twice daily and was followed up for 24 weeks. Clinical outcomes were assessed using the Nail Psoriasis Severity Index (NAPSI) and Dermatology Life Quality Index (DLQI). Following 24 weeks of treatment, nail pitting, onycholysis, subungual hyperkeratosis, and nail thickening showed marked improvement, with NAPSI decreasing from 34 to 5 (85.3% reduction) and DLQI from 22 to 2. No significant adverse events were observed throughout the treatment period. Conclusion: The present report offers preliminary evidence supporting the efficacy of a JAK inhibitor in the treatment of refractory isolated nail psoriasis. Large-scale controlled trials are warranted to confirm long-term safety and clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.